Keybank National Association OH Raises Position in Sanofi $SNY

Posted by Geri Gentry on Jul 7th, 2026

Keybank National Association OH lifted its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 91.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,809 shares of the company’s stock after acquiring an additional 13,265 shares during the quarter. Keybank National Association OH’s holdings in Sanofi were worth $1,340,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in SNY. Advisory Services Network LLC boosted its holdings in Sanofi by 1.4% in the 3rd quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock valued at $743,000 after purchasing an additional 210 shares in the last quarter. Savant Capital LLC increased its position in Sanofi by 2.7% during the 4th quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock worth $418,000 after purchasing an additional 225 shares during the period. Wesbanco Bank Inc. raised its stake in shares of Sanofi by 4.9% during the 4th quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock worth $239,000 after buying an additional 230 shares in the last quarter. IFG Advisory LLC lifted its holdings in shares of Sanofi by 2.7% in the 4th quarter. IFG Advisory LLC now owns 9,213 shares of the company’s stock valued at $446,000 after buying an additional 244 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in shares of Sanofi by 5.5% in the 4th quarter. GAMMA Investing LLC now owns 5,058 shares of the company’s stock valued at $245,000 after buying an additional 264 shares during the period. 14.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. Weiss Ratings raised Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Argus raised shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Morgan Stanley set a $52.00 price target on shares of Sanofi in a research note on Friday, May 1st. Finally, BNP Paribas Exane cut shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $51.00.

View Our Latest Report on SNY

Sanofi Price Performance

Shares of SNY traded up $0.58 on Tuesday, reaching $43.19. The stock had a trading volume of 278,502 shares, compared to its average volume of 3,650,400. Sanofi has a twelve month low of $40.89 and a twelve month high of $52.68. The firm has a market capitalization of $104.71 billion, a PE ratio of 12.06, a PEG ratio of 1.07 and a beta of 0.34. The firm has a 50-day moving average of $43.59 and a 200 day moving average of $45.79. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which was paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th were issued a $2.4225 dividend. This represents a yield of 559.0%. This is a positive change from Sanofi’s previous annual dividend of $2.04. The ex-dividend date of this dividend was Monday, May 4th. Sanofi’s dividend payout ratio is currently 49.16%.

Sanofi Company Profile

(Free Report)

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.